Applied Therapeutics — Technical Presentation (April 2023)
16 slides from Applied Therapeutics's technical presentation, Apr 24, 2023
Slide 1: ACTION-Galactosemia Kids (AT-007-1002) Clinical Trial Update
ACTION-Galactosemia Kids (AT-007-1002) Clinical Trial Update April 24, 2023
Slide 2: Disclaimer
Disclaimer The information contained herein is strictly confidential and is being provided to you solely for your information and to assist you in making your own evaluation of Applied Therapeutics, Inc. (the “Company”). For the purposes of this disclaimer, the presentation includes all statements m
Slide 3: Overview
Overview • We believe that govorestat (AT-007) impacts clinically meaningful aspects of the Galactosemia disease phenotype alongside a favorable safety profile, and we plan to seek approval in both US and EU based on current data. • Govorestat has previously demonstrated a significant reduction in g
Slide 4: Next Steps and Market Opportunity
Next Steps and Market Opportunity • If approved, govorestat will be the first and only treatment for Galactosemia, a devastating rare neurological disease that progressively worsens over time; dietary restriction prevents death, but does not prevent progression of long-term complications of Galactos
Slide 5: ACTION-Galactosemia Kids Pediatric Registrational Clinical Study
5 AT-007 ACTION-Galactosemia Kids Pediatric Registrational Clinical Study (47 Children Age 2-17) AT-007 Dose Escalation Biomarker Assessment of Galactitol Placebo cross to active once treatment effect on outcomes is demonstrated PK/PD Dose Range Finding & Biomarker Data Long-Term Clinical Outcomes P
Slide 6: Compelling Improvement in Primary Endpoint over 18 Months Across Multiple Clinical Domains
6 Activities of Daily Living (BASC-ADL); Behavior (BASC-Behavioral Index); Speech includes Expressive Language (OWLS-OE) & Receptive Language (OWLS-LC) Sensitivity analysis including 9-Hole PegBoard Test p = 0.0937 at 18 months) Baseline Month 6 Month 12 Month 18 Mean Composite Score (Scaled) Baseli
Slide 7: Improvement in Galactitol Biomarker Translates into Consistent Clinical Benefit
Improvement in Galactitol Biomarker Translates into Consistent Clinical Benefit Across Activities of Daily Living, Behavior, Cognition, Adaptive Skills and Tremor 7 Weight Group AT-007 Dose (QD) % Reduction From Baseline >40kg 15mg/kg 38.29% 20-40kg 20mg/kg 41.43% <20kg 30mg/kg 39.83% All groups 15-
Slide 8: Consistent Improvement in Daily Living Skills with Govorestat vs. Placebo
Consistent Improvement on Activities of Daily Living with Govorestat vs. Placebo 8 Biomarker Activities of Daily Living Behavior Cognition Adaptive Skills Tremor Baseline Month 6 Month 12 Month 18 Mean Change From Baseline Score p= 0.0519 Improvement in Activities of Daily Living (ADL) as Measured b
Slide 9: Consistent Improvement in Behavioral Symptoms with Govorestat vs. Placebo
Consistent Improvement in Behavioral with Govorestat vs. Placebo 9 Biomarker Activities of Daily Living Behavior Cognition Adaptive Skills Tremor Baseline Month 6 Month 12 Month 18 Mean Change From Baseline Score p=0.1045 Improvement in Behavioral Symptoms Index as Measured by BASC govorestat placeb
Slide 10: Consistent Improvement in Cognition with Govorestat vs. Placebo
Consistent Improvement in Cognition with Govorestat vs. Placebo 10 Biomarker Activities of Daily Living Behavior Cognition Adaptive Skills Tremor Baseline Month 6 Month 12 Month 18 Mean Change From Baseline Score Improvement in Cognition as Measured by NIH Toolbox Cognition Battery p= 0.2625 govores
Slide 11: Consistent Improvement in Adaptive Skills with Govorestat vs. Placebo
Consistent Improvement in Adaptive Skills with Govorestat vs. Placebo 11 Biomarker Activities of Daily Living Behavior Cognition Adaptive Skills Tremor Improvement in Adaptive Skills as Measured by BASC Baseline Month 6 Month 12 Month 18 Mean Change From Baseline Score p= 0.0265 govorestat placebo
Slide 12: Consistent Improvement in Tremor with Govorestat vs. Placebo
Consistent Improvement in Tremor with Govorestat vs. Placebo 12 Biomarker Activities of Daily Living Behavior Cognition Adaptive Skills Tremor Baseline Month 6 Month 12 Month 18 Mean Change From Baseline Score Improvement in Tremor as Measured by Archimedes Spiral Drawing Test p= 0.0428 Note: Spiral
Slide 13: Safety Summary
Safety Summary 13 • All AEs were mild to moderate • AEs & lab values between AT-007 and placebo groups were balanced Placebo (N=16) Number (%) of Subjects Govorestat (N=31) Number (%) of Subjects Subjects Reporting at Least One TEAE 16 (100%) 30 (96.8%) Gastrointestinal disorders 11 (68.8%) 23 (74.2
Slide 14: Key Projected Milestones by Program
Full Enrollment Completed 15 Month Clinical Outcomes Primary Endpoint Peak VO2 27 Month Clinical Outcomes including morbidity/ mortality DbCM DbCM Phase 3 Key Projected Milestones by Program 14 2022 2023 2024 3 Month Biomarker Data – Sorbitol & NFL 12 Month & Clinical Outcomes Data 24 Month Data Cli
Slide 15: Appendix
APPLIED. Appendix
Slide 16: Speech Endpoints Were Not Impacted by Govorestat Treatment
16 Expressive Language (OWLS-OE) Baseline Month 6 Month 12 Month 18 Mean Change From Baseline Score Baseline Month 6 Month 12 Month 18 Receptive Language (OWLS-LC) Mean Change From Baseline Score p=0.8169 p=0.8536 Speech Endpoints Were Not Impacted by Govorestat Treatment, Likely Due to Speech Thera
Applied Therapeutics — Technical Presentation (April 2023) on 6ix